Insights

Axinn Viewpoints

Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed

Pursuant to the Inflation Reduction Act (the “IRA”), the Secretary of Health and Human Services (“HHS”) and the Center for Medicare & Medicaid Services (“CMS”) have begun the annual process of negotiating with pharmaceutical companies regarding the price of certain drugs covered under Medicare Part D and Part B in an attempt to reduce drug prices.

Learn More

Awards & Recognitions

Axinn Wins Firm of the Year – Americas at 2026 Global Competition Review Awards

Axinn is proud to announce that it was named GCR “Firm of the Year – Americas,” recognizing an exceptional year defined by the quality and impact of the firm’s antitrust work. This is the fourth time the firm has won this award, reflecting Axinn’s continued growth, deep bench of talent, and success guiding clients through complex, high-stakes competition matters.

Learn More

Axinn Viewpoints

Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed

Pursuant to the Inflation Reduction Act (the “IRA”), the Secretary of Health and Human Services (“HHS”) and the Center for Medicare & Medicaid Services (“CMS”) have begun the annual process of negotiating with pharmaceutical companies regarding the price of certain drugs covered under Medicare Part D and Part B in an attempt to reduce drug prices.

Learn More

Awards & Recognitions

Axinn Wins Firm of the Year – Americas at 2026 Global Competition Review Awards

Axinn is proud to announce that it was named GCR “Firm of the Year – Americas,” recognizing an exceptional year defined by the quality and impact of the firm’s antitrust work. This is the fourth time the firm has won this award, reflecting Axinn’s continued growth, deep bench of talent, and success guiding clients through complex, high-stakes competition matters.

Learn More

Axinn Viewpoints

Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed

Pursuant to the Inflation Reduction Act (the “IRA”), the Secretary of Health and Human Services (“HHS”) and the Center for Medicare & Medicaid Services (“CMS”) have begun the annual process of negotiating with pharmaceutical companies regarding the price of certain drugs covered under Medicare Part D and Part B in an attempt to reduce drug prices.

Learn More

Practices

Type

People

Most recent

17 results

February 2, 2026

Axinn Receives Multiple LCLD Awards; Announces 2026 Fellows and Pathfinders

Axinn announced today that the Firm has been named a Top Performer and Compass Award winner by the Leadership Council on Legal Diversity (LCLD), recognizing organizations that demonstrate a sustained commitment to building a more inclusive legal profession through measurable participation and leadership engagement.

Workplace Culture & Opportunity

January 7, 2026

Axinn Promotes Lindsey Strang Aberg, Rebecca L. Clegg, Allison Vissichelli, and Eva Yung to Partner; Ricardo Camposanto, Danielle D. Irvine, and Josh Jowdy to Counsel

Axinn, Veltrop & Harkrider LLP is pleased to announce that it has promoted Lindsey Strang Aberg, Rebecca L. Clegg, Allison Vissichelli, and Eva Yung to partner, and Ricardo Camposanto, Danielle D. Irvine, and Josh Jowdy to counsel, effective January 1, 2026.

News

Antitrust

July 17, 2025

Axinn Attorneys Named to the 2025 Lawdragon 500 X – The Next Generation Guide

Axinn is proud to announce that Lawdragon has recognized 15 of our attorneys in its 2025 edition of the Lawdragon 500 X – The Next Generation guide.

Awards & Recognitions

Antitrust

June 11, 2025

Axinn Recognized by Legal 500 2025 U.S. Guide for Excellence in Antitrust and Litigation

Axinn has once again been named a leading law firm in the Legal 500 2025 U.S. guide, earning top rankings in Antitrust: Cartel, Civil Litigation/Class Actions: Defense, and Merger Control.

Awards & Recognitions